Literature DB >> 15229798

Congenital myasthenic syndromes.

C Michel Harper1.   

Abstract

Congenital myasthenic syndromes are genetic disorders of neuromuscular transmission that should be considered in the differential diagnosis of seronegative myasthenia gravis and other neuromuscular disorders. They are present at birth but may not manifest until childhood or adult life. A classification system of congenital myasthenic syndromes based on molecular genetics is under evolution. Clinical and neurophysiological correlations with molecular studies have defined diagnostic criteria that assist the clinician in identifying specific clinical myasthenic syndromes. Some types of congenital myasthenia (e.g., slow-channel and fast-channel syndrome, acetylcholinesterase deficiency, and choline acetyltransferase deficiency) can be identified by clinical features, response to cholinesterase inhibitors, and standard electrodiagnostic studies. The molecular genetics, pathogenesis, clinical features, differential diagnosis, natural history, and treatment of well-characterized congenital myasthenic syndromes are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229798     DOI: 10.1055/s-2004-829592

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  7 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship.

Authors:  Rawiphan Witoonpanich; Teeratorn Pulkes; Charungthai Dejthevaporn; Praphan Yodnopklao; Pirada Witoonpanich; Suppachok Wetchaphanphesat; Joan M Brengman; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-03       Impact factor: 4.296

3.  Choline transporter hemizygosity results in diminished basal extracellular dopamine levels in nucleus accumbens and blunts dopamine elevations following cocaine or nicotine.

Authors:  Yu Dong; John A Dani; Randy D Blakely
Journal:  Biochem Pharmacol       Date:  2013-08-09       Impact factor: 5.858

Review 4.  Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

Authors:  José David Otero-Cruz; Carlos Alberto Báez-Pagán; Luisamari Dorna-Pérez; Gary Emanuel Grajales-Reyes; Rosaura Teresa Ramírez-Ordoñez; Carlos A Luciano; Christopher Manuel Gómez; José Antonio Lasalde-Dominicci
Journal:  P R Health Sci J       Date:  2010-03       Impact factor: 0.705

5.  Makaluvamine G from the Marine Sponge Zyzzia fuliginosa Inhibits Muscle nAChR by Binding at the Orthosteric and Allosteric Sites.

Authors:  Denis S Kudryavtsev; Ekaterina N Spirova; Irina V Shelukhina; Lina V Son; Yana V Makarova; Natalia K Utkina; Igor E Kasheverov; Victor I Tsetlin
Journal:  Mar Drugs       Date:  2018-03-28       Impact factor: 5.118

6.  Congenital myasthenic syndromes.

Authors:  Josef Finsterer
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

7.  Congenital myasthenic syndromes: Clinical and molecular report on 7 Sicilian patients.

Authors:  Piero Pavone; Agata Polizzi; Maria Roberta Longo; Katia Romano; Michele Vecchio; Andrea D Praticò; Raffaele Falsaperla
Journal:  J Pediatr Neurosci       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.